There was some commentary – albeit brief, top-line analysis – of AstraZeneca PLC (LSE:AZN)’s third-quarter numbers on Friday.
The figures undershot pre-results estimates, prompting a 5% fall in the value of the business on the day.
Deutsche Bank said it expected ‘normal service’ to be resumed in the fourth quarter.
UBS said the sales (excluding COVID vaccine revenues) were ‘okay’ but the operating expenditure lines were‘ heavy’. The Swiss bank repeated its ‘buy’ and £100 price target.
Deutsche also remains a ‘buyer’ of the stock up to £105.
Of the 27 brokers and banks covering AZ, 23 have positive calls. The consensus valuation for the shares is £103.